What is Cerus?
Headquartered in Concord, California, Cerus is dedicated to developing and commercializing the INTERCEPT Blood System. This innovative pathogen-reduction technology is designed for use by blood centers and hospitals to inactivate a broad spectrum of viruses, bacteria, and parasites present in blood components, including platelets and plasma. The company is also advancing programs focused on red blood cells, aiming to further broaden the application of its life-saving technology. Cerus operates within the vital intersection of medical technology and public health, addressing the ongoing need for safer blood transfusions.
How much funding has Cerus raised?
Cerus has raised a total of $378.6M across 8 funding rounds:
Stock Offering
$21.3M
Debt
$10M
Debt
$30M
Debt
$40M
Debt
$90M
Stock Offering
$63.3M
Unspecified
$14M
Debt
$110M
Stock Issuance/Offering (1997): $21.3M with participation from Undisclosed
Debt (2010): $10M led by Oxford Finance Corporation
Debt (2014): $30M supported by Oxford Finance
Debt (2017): $40M featuring Oxford Finance Corporation
Debt (2019): $90M backed by MidCap Financial
Stock Issuance/Offering (2020): $63.3M with participation from Undisclosed
Unspecified (2020): $14M led by Biomedical Advanced Research and Development Authority
Debt (2026): $110M supported by MidCap Financial
Key Investors in Cerus
Oxford Finance
Oxford Finance, established in 2002 and based in Alexandria, Virginia, is a specialty finance firm providing adaptable financial solutions to healthcare and life sciences companies globally. They have been a consistent debt provider to Cerus.
MidCap Financial
MidCap Financial specializes in tailoring flexible and efficient financing solutions, particularly for companies seeking rapid capital deployment. They have provided debt financing to Cerus.
Biomedical Advanced Research and Development Authority
The Biomedical Advanced Research and Development Authority (BARDA) is a U.S. government agency focused on supporting the development of medical countermeasures against chemical, biological, radiological, and nuclear threats, as well as pandemic influenza and emerging infectious diseases. Their investment indicates a strategic alignment with public health security.
What's next for Cerus?
With the recent influx of $110M in strategic capital, Cerus is poised for significant expansion and further technological development. The company's focus on pathogen reduction in blood products positions it as a key player in global blood safety initiatives. Future endeavors will likely involve scaling manufacturing, expanding clinical applications, and potentially exploring new therapeutic areas where pathogen inactivation is critical. The substantial enterprise-level backing of $378.6M provides Cerus with the financial runway to pursue these ambitious goals and solidify its market leadership.
See full Cerus company page
